AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.

Positive

• Ongoing focus on research and development of therapeutics for multiple diseases.
• Commitment to addressing significant health issues like COVID-19.

Negative

• Postponement of investor conference call may lead to uncertainty among investors.

OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels’ mother over this past weekend.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

FAQ

What caused AIM ImmunoTech to postpone its investor conference call?

The investor conference call was postponed due to the death of CEO Thomas K. Equels' mother.

When will the rescheduled investor conference call for AIM ImmunoTech take place?

The new date for the investor conference call has not yet been announced.

What is AIM ImmunoTech focused on in its research?

AIM ImmunoTech is focused on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.